0257 GMT - Ansell is likely to be the Australian healthcare stock that is most exposed to the impact of U.S. tariffs, Citi analysts write in a note. They acknowledge that breath-tech maker ResMed and medical-tech provider Nanosonics are probably impacted, given their manufacturing footprints, but not to the same extent as Ansell. The personal-protective equipment maker sources a majority of its products from Malaysia and Sri Lanka, both of which are among the countries hardest hit by tariffs, generating more than 40% of its revenue from the U.S. The exclusion of pharmaceuticals from tariffs is a relief for vaccine maker CSL, they add. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
April 03, 2025 22:57 ET (02:57 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。